Medicus 2013;22(2):83-87
87
Jedinstveni dišni putovi – terapijske implikacije
6.
BRESCIANI M, PARADIS L, Des ROCHES A i sur. Rhinosinusitis in
severe asthma. J Allergy Clin Immunol 2001;107:73-80.
7.
GUERRA S, SHERRILL DL, MARTINEZ FD i sur. Rhinitis as an inde-
pendent risk factor for adult-onset asthma. J Allergy Clin Immunol
2002;109:419-25.
8.
FASANOMB. Combined airways: impact of upper airway on lower ai-
rway. Curr OpinOtolaryngol HeadNeck Surg 2010;18:15-20.
9.
DENBURG JA, KEITHPK. Eosinophil progenitors in airway diseases:
clinical implications. Chest 2008;134:1037-43.
10. CYRMM, HAYES LM, CRAWFORDL i sur. The effect of desloratadine
on eosinophil/basophil progenitors and other inflammatorymarkers
in seasonal allergic rhinitis: a placebo controlled randomized study.
Int ArchAllergy Immunol 2005;138:209-16.
11. BRAUNSTAHLGJ. The unified immune system: respiratory tract-na-
sobronchial interaction mechanisms in allergic airway disease. J
Allergy Clin Immunol 2005;115:142-8.
12. PRICE D i sur. Effect of a concomitant diagnosis of allergic rhini-
tis on asthma-related health care use of adults. Clin Exp Allergy
2005;35:282-7.
13. BOUSQUET J i sur. Increased risk of asthma attacks and emergen-
cy visits among asthma patients with allergic rhinitis: a subgroup
analysis of the investigation of montelukast as a partner agent for
complementary therapy. Clin ExpAllergy 2005;35:723-7.
14. ADAMSRJ, FUHLBRIGGEAL, FINKELSTEINJA,WEISS ST. Intrana-
sal steroids and the risk of emergency department visits for asthma. J
Allergy Clin Immunol 2002;109:636-42.
15. De GROOT EP, NIJKAMP A, DUIVERMAN EJ, BRAND PL. Allergic
rhinitis is associated with poor asthma control in children with asth-
ma. Thorax 2012;67:582-7.
16. CORREN J, ADINOFF AD, BUCHMEIER AD, IRVIN CG. Nasal beclo-
methasone prevents the seasonal increase in bronchial responsive-
ness in patients with allergic rhinitis and asthma. J Allergy Clin Im-
munol 1992;90:250-6.
17. AGONDI RC, MACHADO ML, KALIL J, GIAVINA-BIANCHI P. Intra-
nasal corticosteroid administration reduces nonspecific bronchial
hyperresponsiveness and improves asthma symptoms. J Asthma
2008;45:754-7.
18. MARPLE BF. Allergic rhinitis and inflammatory airway disease: inte-
ractionswithintheunifiedairspace.AmJRhinolAllergy2010;24:249-
54.
19. TARAMARCAZ P, GIBSON PG. Intranasal corticosteroids for asthma
control in people with coexisting asthma and rhinitis. Cochrane Da-
tabase Syst Rev 2003;4:CD003570.
20. DAHL R, NIELSEN LP, KIPS J i sur. The SPIRA Study Group. Intra-
nasal and inhaled fluticasone propionate for pollen-induced rhinitis
and asthma. Allergy 2005;60:875-81.
21. NATHANRA,YANCEYSW,WAITKUS-EDWARDSKisur.Fluticasone
propionate nasal spray is superior to montelukast for allergic rhinitis
while neither affects overall asthma control. Chest 2005;128:1910-20.
22. PRICE D. Asthma and allergic rhinitis: Linked in treatment and out-
comes. Ann ThoracMed 2010;5:63-4.
23. PRICEDB, HERNANDEZD,MAGYARP i sur. Randomised controlled
trial of montelukast plus inhaled budesonide versus double dose in-
haled budesonide in adult patients with asthma. Thorax 2003;58:211-
6.
24. PRICE DB, SWERN A, TOZZI CA i sur. Effect of montelukast on lung
function in asthma patients with allergic rhinitis: analysis from the
COMPACT trial. Allergy 2006;61:737-42.
25. NATHAN RA. Pharmacotherapy for allergic rhinitis: a critical review
of leukotriene receptor antagonists compared with other treatments.
AnnAllergy Asthma Immunol 2003;90:182-90.
26. WILSON AM, O’BYRNE PM, PARAMESWARAN K. Leukotriene re-
ceptor antagonists for allergic rhinitis: a systematic review and me-
ta-analysis. AmJMed 2004;116:338-44.
27. SIN DD, MAN J, SHARPE H i sur. Pharmacological management to
reduce exacerbations in adults with asthma: a systematic review and
meta-analysis. JAMA 2004;292:367-76.
28. HALPERN MT, KHAN ZM, STANFORD RH i sur. Asthma: resource
use and costs for inhaled corticosteroid vs leukotriene modifier tre-
atment: ameta-analysis. J FamPract 2003;52:382-9.
29. CRETICOS P, KNOBIL K, EDWARDS LD i sur. Loss of response to tre-
atment with leukotriene receptor antagonists but not inhaled corti-
costeroids in patients over 50 years of age. Ann Allergy Asthma Im-
munol 2002;88:401-9.
30. VALOVIRTA E. Managing co-morbid asthma with allergic rhinitis:
targeting the one-airway with leukotriene receptor antagonists. WAO
Journal 2012;5:S210-1.
31. CASALETB, STOKES J. Anti-IgE therapy: clinical utility beyond asth-
ma. J Allergy Clin Immunol 2009;123:770-1.
32. BEEH KM, BEIER J, KORNMANN O i sur. A single nasal allergen
challenge increases induced sputum inflammatory markers in
non-asthmatic subjects with seasonal allergic rhinitis: correlation
with plasma interleukin-5. Clin ExpAllergy 2003;33:475-82.
33. BONAYM, NEUKIRCHC, GRANDSAIGNEMi sur. Changes inairway
inflammation following nasal allergic challenge in patients with sea-
sonal rhinitis. Allergy 2006;61:111-8.
Prof. dr. sc. Neven Tudorić, dr. med.
KB Dubrava
Pulmološki odjel Interne klinike KB Dubrava, Zagreb
10000 Zagreb, Avenija Gojka Šuška 6
3. 4. 2013.
April 3, 2013
30. 4. 2013.
April 30, 2013
ADRESA ZA DOPISIVANJE:
PRIMLJENO/RECEIVED:
PRIHVAĆENO/ACCEPTED:
